Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel López de Rodas(Yale Cancer Center), Kurt A. Schalper(Yale University)
Cited by 123
Related Papers
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
|JAMA Oncology|2022|383
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
|Journal for ImmunoTherapy of Cancer|2019|195
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
|Nature Communications|2018|189